158 related articles for article (PubMed ID: 31770784)
1. Evaluation of Different Types of Natural Surfactants by Lung Ultrasound in Respiratory Distress Syndrome.
Bozkaya D; Dizdar EA; Korkut S; Ceran B; Alkan M; Oğuz ŞS
Am J Perinatol; 2021 May; 38(6):590-596. PubMed ID: 31770784
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
[TBL] [Abstract][Full Text] [Related]
3. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
4. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
[TBL] [Abstract][Full Text] [Related]
6. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
7. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
[TBL] [Abstract][Full Text] [Related]
8. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
10. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
[TBL] [Abstract][Full Text] [Related]
11. Effects of Two Different Exogenous Surfactant Preparations on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants with Severe Respiratory Distress Syndrome.
Terek D; Gonulal D; Koroglu OA; Yalaz M; Akisu M; Kultursay N
Pediatr Neonatol; 2015 Aug; 56(4):248-55. PubMed ID: 25603725
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three natural surfactants according to lung ultrasonography scores in newborns with respiratory distress syndrome.
Dilli D; Çakmakçı E; Akduman H; Oktem A; Aydoğan S; Çitli R; Zenciroğlu A
J Matern Fetal Neonatal Med; 2021 May; 34(10):1634-1640. PubMed ID: 31296073
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of surfactant preparations in premature infants.
Trembath A; Hornik CP; Clark R; Smith PB; Daniels J; Laughon M;
J Pediatr; 2013 Oct; 163(4):955-60.e1. PubMed ID: 23769501
[TBL] [Abstract][Full Text] [Related]
15. Surfactant Administration in Preterm Infants: Drug Development Opportunities.
Taylor G; Jackson W; Hornik CP; Koss A; Mantena S; Homsley K; Gattis B; Kudumu-Clavell M; Clark R; Smith PB; Laughon MM
J Pediatr; 2019 May; 208():163-168. PubMed ID: 30580975
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
Malloy CA; Nicoski P; Muraskas JK
Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Complications in Premature Infants Using a Beractant or Poractant for Respiratory Distress Syndrome: A Retrospective Cohort Study.
Wong KL; Siu KL
Am J Perinatol; 2024 Apr; 41(5):641-648. PubMed ID: 35098502
[TBL] [Abstract][Full Text] [Related]
18. From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy.
Bianco F; Ricci F; Catozzi C; Murgia X; Schlun M; Bucholski A; Hetzer U; Bonelli S; Lombardini M; Pasini E; Nutini M; Pertile M; Minocchieri S; Simonato M; Rosa B; Pieraccini G; Moneti G; Lorenzini L; Catinella S; Villetti G; Civelli M; Pioselli B; Cogo P; Carnielli V; Dani C; Salomone F
Respir Res; 2019 Jul; 20(1):134. PubMed ID: 31266508
[TBL] [Abstract][Full Text] [Related]
19. Bovine or Porcine: Does the Type of Surfactant Matter?
Boshoff Coyles L; Joolay Y; Tooke L
J Trop Pediatr; 2020 Oct; 66(5):534-541. PubMed ID: 32112649
[TBL] [Abstract][Full Text] [Related]
20. The Role of Lung Ultrasound as an Early Diagnostic Tool for Need of Surfactant Therapy in Preterm Infants with Respiratory Distress Syndrome.
Vardar G; Karadag N; Karatekin G
Am J Perinatol; 2021 Dec; 38(14):1547-1556. PubMed ID: 32674204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
